These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 28367235)
21. Aberrant mTOR/autophagy/Nurr1 signaling is critical for TSC-associated tumor development. Wang Y; Li C; Zhang Y; Zha X; Zhang H; Hu Z; Wu C Biochem Cell Biol; 2021 Oct; 99(5):570-577. PubMed ID: 34463540 [TBL] [Abstract][Full Text] [Related]
22. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707 [TBL] [Abstract][Full Text] [Related]
23. A mouse model of craniofacial bone lesion of tuberous sclerosis complex. Fang F; Wei X; Hu M; Liu F Musculoskelet Regen; 2015; 1(1):. PubMed ID: 26052552 [TBL] [Abstract][Full Text] [Related]
24. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M; Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042 [TBL] [Abstract][Full Text] [Related]
25. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
27. Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Cox RL; Calderon de Anda F; Mangoubi T; Yoshii A Front Mol Neurosci; 2018; 11():409. PubMed ID: 30467464 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821 [TBL] [Abstract][Full Text] [Related]
29. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1 Shen MH; Samsel P; Shen LL; Narov K; Yang J; Sampson JR Transl Oncol; 2017 Oct; 10(5):793-799. PubMed ID: 28844017 [TBL] [Abstract][Full Text] [Related]
30. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809 [TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760 [TBL] [Abstract][Full Text] [Related]
32. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis. Kim WS Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518 [TBL] [Abstract][Full Text] [Related]
33. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies. McEneaney LJ; Tee AR Adv Genet; 2019; 103():91-118. PubMed ID: 30904097 [TBL] [Abstract][Full Text] [Related]
34. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095 [TBL] [Abstract][Full Text] [Related]